Picture of Aarti Pharmalabs logo

AARTIPHARM Aarti Pharmalabs Share Price

0.000.00%
in flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Momentum

Relative Strength (%)
1m-12.8%
3m-11.37%
6m-6.15%
1yr+17.88%
Volume Change (%)
10d/3m-7.78%
Price vs... (%)
52w High-18.77%
50d MA-8.23%
200d MA+6.36%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value2.52
Price to Tang. Book2.62
Price to Free Cashflow29.12
Price to Sales2.28
EV to EBITDA12.24

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital15.9%
Return on Equity12.17%
Operating Margin15.22%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Aarti Pharmalabs EPS forecast chart

Profile Summary

Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), xanthine derivatives, and allied products, situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, and others. Its Caffeine products include caffeine anhydrous, and caffeine anhydrous (granules).

Directors

    Last Annual
    March 31st, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    November 22nd, 2019
    Public Since
    January 30th, 2023
    No. of Shareholders
    285,417
    No. of Employees
    1,400
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    in flag iconNational Stock Exchange of India
    Shares in Issue
    90,620,000

    AARTIPHARM Share Price Performance

    Similar to AARTIPHARM

    Picture of Aarey Drugs and Pharmaceuticals logo

    Aarey Drugs and Pharmaceuticals

    in flag iconNational Stock Exchange of India

    Picture of Aarti Drugs logo

    Aarti Drugs

    in flag iconNational Stock Exchange of India

    Picture of Abbott India logo

    Abbott India

    in flag iconNational Stock Exchange of India

    Picture of Accent Microcell logo

    Accent Microcell

    in flag iconNational Stock Exchange of India

    Picture of Ajanta Pharma logo

    Ajanta Pharma

    in flag iconNational Stock Exchange of India

    FAQ